We have collected information about Intraperitoneal Drug Delivery for you. Follow the links to find out details on Intraperitoneal Drug Delivery.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2854252/
IP drug delivery helps in the regional therapy of these disorders by providing relatively high concentration and longer half-life of a drug in the peritoneal cavity. Various studies suggest that IP delivery of anti-neoplastic agents is a promising approach for malignancies in the peritoneal cavity compared to the systemic administration.Author: Gaurav Bajaj, Yoon Yeo
https://www.cancernetwork.com/oncology-journal/intraperitoneal-drug-delivery-ovarian-cancer-why-how-who-what-and-when
In 1996, intraperitoneal (IP) administration of cisplatin plus intravenous (IV) cyclophosphamide proved superior to both drugs given intravenously at the same doses—which, at the time, was the standard treatment in the United States.Author: Maria Jose Echarri Gonzalez, Robin Green, Franco M. Muggia
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(03)01074-X/fulltext
The use of intraperitoneal drug delivery in the treatment of malignant disease confined to the peritoneal cavity is based on the theoretical potential for increased exposure of the tumour to antineoplastic agents leading to improved cytotoxicity.Author: Maurie Markman
https://www.hindawi.com/journals/tswj/2013/720858/
Because of the fast clearance of the conventional intravenous (IV) drug delivery systems used for IP therapy, a lot of research is performed to optimize IP drug delivery and extend the residence time of the cytotoxic agent in the peritoneal cavity.Author: L. De Smet, W. Ceelen, J. P. Remon, C. Vervaet
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6968566/
Intraperitoneal (IP) drug delivery represents an attractive strategy for the local treatment of peritoneal metastasis (PM). PM is characterized by the presence of widespread metastatic tumor nodules on the peritoneum, mostly originating from gastro-intestinal or gynaecological cancers.Author: Leen Van de Sande, Sarah Cosyns, Wouter Willaert, Wim Ceelen
https://www.tandfonline.com/doi/pdf/10.1080/10717544.2016.1269848
The intraperitoneal (IP) administration of chemotherapy is an alternative treatment for peritoneal carcinomatosis, allowing for higher intratumor concentrations of the cytotoxic agent compared to intravenous administration. Nevertheless, drug penetration depths are still limited to a few millimeters.Author: Margo Steuperaert, Giuseppe Falvo D’Urso Labate, Charlotte Debbaut, Olivier De Wever, Christian Vanh...
https://www.sciencedirect.com/topics/medicine-and-dentistry/intraperitoneal-drug-administration
Intraperitoneal injection is widely used in rodents as a route of drug administration. Intraperitoneally applied drug forms are supposed to be located in the peritoneal cavity. The disappearance of drugs from the peritoneal cavity upon injection is because of diffusion into the surrounding tissues.
https://en.wikipedia.org/wiki/Intraperitoneal_injection
Intraperitoneal injection or IP injection is the injection of a substance into the peritoneum (body cavity). It is more often applied to animals than to humans. In general, it is preferred when large amounts of blood replacement fluids are needed or when low blood pressure or other problems prevent the use...
https://www.researchgate.net/post/How_do_drugs_get_into_the_circulation_by_intraperitoneal_injection
Intraperitoneal injection (IP injection) is a common used method in animal study. I found that the pharmacokinetic of a drug given by IP was different to that by gavage. Apart from that the bioavailability of IP is higher than gavage, I wonder if there is any difference in the way the drug …
https://www.cancernetwork.com/oncology-journal/intraperitoneal-drug-delivery-ovarian-cancer-why-how-who-what-and-when/page/0/1
Oct 28, 2019 · IP drug delivery is an old topic. The fact that the administration of IP chemotherapy is more complex and time-consuming than IV chemotherapy, has been associated with a greater risk of toxicity, and is both physically and emotionally more challenging for patients continues to shape the nonacceptance of this modality by clinicians.Author: Maria Jose Echarri Gonzalez, Robin Green, Franco M. Muggia
Searching for Intraperitoneal Drug Delivery?
You can just click the links above. The data is collected for you.
